<?xml version="1.0" encoding="UTF-8"?>
<ref id="BST-47-1757C103">
 <label>103</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Bonner</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Karlsson</surname>
    <given-names>I.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Rodolfo</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Arnold</surname>
    <given-names>R.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Vergani</surname>
    <given-names>E.</given-names>
   </name> and 
   <name name-style="western">
    <surname>Arbiser</surname>
    <given-names>J.</given-names>
   </name>
  </person-group> (
  <year>2016</year>) 
  <article-title>Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo</article-title>. 
  <source>Oncotarget</source>
  <volume>7</volume>
  <pub-id pub-id-type="doi">10.18632/oncotarget.7289</pub-id>
 </mixed-citation>
</ref>
